Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S. Datoo, Halidou Tinto, Toussaint Rouamba et al.|The Lancet Infectious Diseases|2022Cited by 285
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Peter Winskill, Hillary M. Topazian et al.|The Lancet Infectious Diseases|2024Cited by 48